Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia.Safety Issues
Latest Information Update: 30 Jul 2019
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Trigeminal neuralgia
- Focus Adverse reactions
- 30 Jul 2020 However, the primary efficacy outcome is also stated as main efficacy endpoint (MEO) & as secondary outcome of this study in rest of the same results source (3411796).In this case, main efficacy endpoint is not the primary endpoint of the study rather it is MEO amongst all other efficacy endpoints. Hence, retained only safety as primary endpoint of this study.
- 25 Jul 2019 Results assessing the safety and preliminary efficacy of injecting onabotulinumtoxinA (BTA) toward the sphenopalatine ganglion using the MultiGuide in patients with refractory classical trigeminal neuralgia, were published in the Headache Journal.
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.